Sense
：5’ATGAAAGTCTCCACAGCGTTT3’
Antisense
：5’TTACGGCTTTGTAGTTTGGGA3’
β
-actin 279b
Sense
：5’CCAACTGGGACGACATGGAG3’
Antisense
：5’CATACCCCTCGTAGATGGGC3’
PCR
はサーマルサイクラー（PERKIN ELMER
）を用いて，それぞれ以下の条件で行った．MCP-1
（25 cycle at 95
℃for 1 min, 50
℃for 1 min 72
℃for 1 min
）IL-8
（35 cycle at 95
℃for 1 min, 54
℃for 1 min 72
℃for 1 min
）RANTES
（30 cycle at 95
℃for 1 min, 50
℃for 1 min 72
℃for 1 min
）EOTAXIN
（30 cycle at 95
℃for 1 min, 50
℃for 1 min 72
℃for 1 min
）β-actin
（22 cycle at 95
℃for 1 min, 56
℃for 1 min 72
℃for 1 min
）PCR
後，反応液を2%
アガロースで電気泳動した．いずれのcDNA
も，予想されるbase pair
に特異的なバンドとして検出された．なお，すべてのサンプルにつきRT
反応を行わずにPCR
を行い，genomic DNA
が混入していないことを確認した．6.2.
統計処理実験結果は平均値±標準誤差で示した．統計処理は，
GraphPad Prism ver 2.01
（GraphPad
Software
）を用いて行った．実験結果に対し，3
群以上の群間比較は，多重比較検定によりおこなった，すなわち，
Bartlett
検定により分散の均一性を検定し，分散が均一であった場合には一 元配置分散分析を行い，不均一であった場合にはKruskal-Walis
検定を行い，これらで有意差 が認められた場合に限り，Tukey
またはDunnett
の方法により各群間の有意差検定を行った．また，
2
群間の比較においては，F
検定により母集団の等分散性の検定を行い，等分散の時 はStudent’s
のt
検定を行い，また，不等分散のときはWelch’s
のt
検定を行った．以上の検定 により，危険率が5%
未満の時に有意であると判定した．謝辞
本稿を終えるにあたり，本研究の機会を与えて戴き，終始御懇篤なる御指導，御鞭撻ならびに御高閲を賜 りました熊本大学大学院医学薬学研究部 入江 徹美 教授に深甚なる感謝の意を表します．
本論文作成にあたり御高閲と多くの御助言を賜りました熊本大学大学院医学薬学研究部 宮田 健 教授，
齋藤 秀之 教授に深く感謝の意を表します．
本研究を行うに際し有益なる御指導と御鞭撻を賜りました熊本大学大学院医学薬学研究部 入倉 充 助 教授，森内 宏志 助手に深く感謝の意を表します．
本研究を行うに際し有益なる御鞭撻ならびに多大なるご助力を賜りました熊本大学大学院医学薬学研究 部 礒濱 洋一郎 助教授に深く感謝の意を表します．
本研究を行うに際し有益なる御鞭撻ならびに多大なるご助力を賜りました熊本大学医学部附属病院 病理 部 猪山 賢一 部長，靍田診断外科病理 靍田 潤二 博士に深く感謝の意を表します．
本研究において有益なる御指導と御助力を賜りました熊本大学医学部附属病院 中央検査部 杉内 博幸 博士ならびに中央検査部の皆様および熊本大学医学部附属病院 病理部 病理検査室 徳永 英博 主任 臨床検査技師ならびに病理検査室の皆様に深く感謝の意を表します．
本研究において有益なる御助言と御協力を賜りました 中国 Yanbian University 楊 長青 助教授ならび にイラン Kashan University Saeid Golbidi 博士に心より感謝いたします．
共同研究者として御協力いただき，また苦楽を共にした 畑本 慶太 学士，栗田 澄香 嬢，髙瀬 絢子 学 士ならびに熊本大学大学院薬学教育部 薬剤情報分析学研究室の研究室員の諸氏に心より感謝いたしま す．
本研究を行うにあたり御助言と御協力いただき，また苦楽を共にした 熊本大学大学院薬学研究科薬理学 研究室 大日向 輝 修士，今里 暁 修士ならびに熊本大学大学院薬学教育部薬物活性学研究室の諸氏 に心より感謝いたします．
本研究に用いたトラニラストを恵与くださいましたキッセイ薬品工業株式会社ならびにオザグレルナトリウム を恵与いただいた小野薬品工業株式会社に深く感謝いたします．
最後に，終始あたたかく見守り助けてくださった友人たち，親戚の皆様，祖父母そして両親に感謝いたしま す．
2004年3月 石塚 洋一
参考文献
1) Ware L.B. and Matthay M.A., The acute respiratory distress syndrome, N. Engl. J. Med., 342, 1334-1349 (2000).
2) Vincent J.L., Sakr Y., and Ranieri V.M., Epidemiology and outcome of acute respiratory failure in intensive care unit patients, Crit. Care Med., 31(Suppl), S296-S299 (2003).
3) Nuckton T.J., Alonso J.A., Kallet R.H., Daniel B.M., Pittet J-F., Eisner M.D., and Matthay M.A., Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome, N. Engl. J. Med., 346, 1281-1286 (2002).
4) Ashbaugh D.G., Bigelow D.B., Petty T.L. and Levine B.E., Acute respiratory distress in adults, Lancet, 12, 319-323 (1967).
5) Bannerman D.D. and Goldblum S.E., Mechanisms of bacterial lipopolysaccharide-induced endothelial apoptosis, Am. J. Physiol. Lung Cell Mol. Physiol., 284, L899-914 (2003).
6) Nagase T., Uozumi N., Ishii S., Kume K., Izumi T., Ouchi Y. and Shimizu T., Acute lung injury by sepsis and acid aspiration: A key role for cytosolic phospholipase A2, Nat. Immunol., 1, 42-46 (2000).
7) Endo S., Sohara Y., Murayama F., Yamaguchi T., Hasegawa T. and Kanai Y., Real-time visualization of partial liquid ventilation in a model of acute lung injury, Surgery, 133, 207-215 (2003).
8) Frank J.A., Gutierrez J.A, Jones K.D., Allen L., Dobbs L. and Matthay M.A., Low tidal volume reduces epithelial and endothelial injury in acid-injured rat lungs, Am. J. Respir. Crit. Care Med., 165, 242-249 (2002).
9) Schuster D.P., ARDS: Clinical lessons from the oleic acid model of acute lung injury, Am. J. Respir.
Crit. Care Med., 149, 245-260 (1994).
10) Schweiger J.W., Downs J.B. and Smith R.A., Chest wall disruption with and without acute lung injury: effects of continuous positive airway pressure therapy on ventilation and perfusion relationships, Crit. Care Med., 31, 2364-2370 (2003).
11) Hubloue I., Biarent D., Abdel Kafi S., Bejjani G., Melot C., Naeije R. and Leeman M., Endothelin receptor blockade in canine oleic acid-induced lung injury, Intensive Care Med., 29,1003-1006 (2003).
12) Peitzman A.B., Corbett W.A., Shires G.T., Lynch N.J., and Shires G.T., The effect of increasing
end-expiratory pressure on extravascular lung water, Surgery, 90, 439-445 (1981).
13) Johanson W.G.Jr., Holcomb J.R., and Coalson J.J., Experimental diffuse alveolar damage in baboons, Am. Review of Respiratory Disease, 126,142-151 (1982).
14) Julien M., Hoeffel J.M., and Flick M.R., Oleic acid lung injury in sheep, J. Appl. Physiol., 60, 433-440 (1986).
15) Mintun M.A., Dennis D.R., Welch M.J., Mathias C.J., and Schuster D.P., Measurements of pulmonary vascular permeability with PET and gallium-68 transferrin, J. Nucl. Med., 28, 1704-1716 (1987).
16) Thompson W.K., Marchak B.E., Froese A.B., and Bryan A.C., High-frequency oscillation compared with standard ventilation in pulmonary injury model, J. Appl. Physiol.: Respirat. Environ. Exercise Physiol., 52, 543-548 (1982).
17) Hofman W.F., Ehrhart I.C., Effects of methylprednisolone on fatty acid induced edema in the dog lung, J. Trauma, 21, 878-882 (1981).
18) Hofman W.F., Ehrhart I.C., Granger W.M., and Miller D.A., Sequential cardiopulmonary changes after oleic-acid injury in dogs, Crit. Care Med., 13, 22-27 (1985).
19) Maclver R.W.., Hustead R.F., and Peltier L.F., Alternation of surfactant chemistry in experimental hemorrhagic pancreatitis, J. Surg. Res., 23, 311-314 (1977).
20) Halilton R.W., Hustead R.F., and Peltier L.F., Fat embolism: the effect of particulate embolism on lung surfactant. Surgery St. Louis, 56, 53-56 (1964).
21) Kumar K.V., Manimala R.S., Gayani R., Krishna M.I., and Naidu M.U.R., Oxidant stress and essential fatty acids in patients with risk and established ARDS, Clinica. Chimica. Acta, 298, 111–120 (2000).
22) Rosenthal C., Caronia C., Quinn C., Lugo N. and Sagy M., A comparison among animal models of acute lung injury, Crit. Care Med., 26, 912-916 (1998).
23) Furue S., Kuwabara K., Mikawa K., Nishina K., Shiga M., Maekawa N., Ueno M., Chikazawa Y., Ono T., Hori Y., Matsukawa A., Yoshinaga M., and Obara H., Crucial role of group IIA phospholipase A2 in oleic acid-induced acute lung injury in rabbits, Am. J. Respir. Crit. Care Med., 160, 1292-1302 (1999).
24) Furue S., Mikawa K., Nishina K., Shiga M., Ueno M., Tomita Y., Kuwabara K., Teshirogi I., Ono T., Hori Y., Matsukawa A., Yoshinaga M. and Obara H., Therapeutic time-window of a group IIA
phospholipase A2 inhibitor in rabbit acute lung injury: correlation with lung surfactant protection, Crit.
Care Med., 29, 719-727 (2001).
25) Luecke T., Meinhardt J.P., Herrmann P., Klemm S, Weiss A., Weisser G., Hirschl R.B. and Quintel M., End-expiratory lung volumes and density distribution patterns during partial liquid ventilation in healthy and oleic acid-injured sheep: a computed tomography study, Crit. Care Med., 31, 2190-2197 (2003).
26) Wrigge H., Zinserling J., Neumann P., Defosse J., Magnusson A., Putensen C. and Hedenstierna G., Spontaneous breathing improves lung aeration in oleic acid-induced lung, Anesthesiology, 99, 376-384 (2003).
27) Hering R., Viehofer A., Zinserling J., Wrigge H., Kreyer S., Berg A., Minor T. and Putensen C., Effects of spontaneous breathing during airway pressure release ventilation on intestinal blood flow in experimental lung injury, Anesthesiology, 99, 1137-1144 (2003).
28) Galletti G.G. and Venegas J.G., Tracer kinetic model of regional pulmonary function using positron emission tomography, J. Appl. Physiol., 93, 1104-1114 (2002).
29) King E.G., Wagner W.W. Jr., Ashbaugh D.G., Latham L.P. and Halsey D.R., Alterations in pulmonary microanatomy after fat embolism. In vivo observations via thoracic window of the oleic acid-embolized canine lung, Chest, 59, 524-530 (1971).
30) Skeie B., Askanazi J., Rothkopf M.M., Rosenbaum S.H., Kvetan V., and Thomashow B., Intravenous fat emulsions and lung function: a review, Crit. Care Med., 16, 183-194 (1988).
31) Capper E.A., Roshak A.K., Bolognese B.J., Podolin P.L., Smith T., Dewitt D.L., Anderson K.M. and Marshall L.A., Modulation of human monocyte activities by tranilast, SB 252218, a compound demonstrating efficacy in restenosis, J. Pharmacol. Exp. Ther., 295, 1061-1069 (2000).
32) Suzawa H., Kikuchi S., Ichikawa K. and Koda A., Inhibitory action of tranilast, an anti-allergic drug, on the release of cytokines and PGE2 from human monocytes-macrophages, Jpn. J. Pharmacol., 60, 85-90 (1992).
33) Isaji M., Miyata H. and Ajisawa Y., Tranilast: A new application in the cardiovascular field as an antiproliferative drug, Cardiovasc. Drug Rev., 16, 288-299 (1998).
34) Selig W.M., Patterson C.E., Henry D.P., and Rhoades R.A., Role of histamine in acute oleic acid-induced lung injury, J. Appl. Physiol., 61, 233-239 (1986).
35) Akamatsu H. and Horio T., The possible role of reactive oxygen species generated by neutrophils in mediating acne inflammation. Dermatology, 196, 82-85 (1998).
36) DeLuca P., Rossetti R.G., Alavian C., Karim P., and Zurier R.B., Effects of gammalinolenic acid on interleukin-1 beta and tumor necrosis factor-alpha secretion by stimulated human peripheral blood monocytes: studies in vitro and in vivo, J. Invest. Med., 47,246-250 (1999).
37) Moriuchi H., Zaha M., Fukumoto T., and Yuizono T., Activation of polymorphonuclear leukocytes in oleic acid-induced lung injury, Intensive Care Med., 24, 709-715 (1998).
38) Sun D., Zhao M., Ma D., Liao S., and Di C., Protective effect of interleukin-1 receptor antagonist on oleic acid-induced lung injury, Chin. Med. J., 109, 522-526 (1996).
39) Beilman G., Pathogenesis of oleic acid-induced lung injury in rat: distribution of oleic acid during injury and early endothelial cell changes, Lipids, 30, 817-823 (1995).
40) Moriuchi H., Arai I., and Yuizono T., Tranexamic acid attenuates oleic-acid-induced pulmonary extravasation, Intensive Care Med., 21, 1003-1008 (1995).
41) Yang C., Moriuchi H., Takase J., Ishitsuka Y., Irikura M. and Irie T., Oxidative stress in early stage of acute lung injury induced with oleic acid in guinea pigs, Biol. Pharm. Bull., 26, 424-428 (2003).
42) Kuwabara K., Furue S., Tomita Y., Ueno M., Ono T., Matsukawa A., Yoshinaga M., Mikawa K., Nishina K., Shiga M., Obara H. and Hori Y., Effect of methylprednisolone on phospholipase A2
activity and lung surfactant degradation in acute lung injury in rabbits, Eur. J. Pharmacol., 433, 209-216 (2001).
43) Fuhrman T.M. Hollon M.F., Reines H.D., Olanoff L.S. and Halushka P.V., Beneficial effects of ibuprofen in oleic acid induced lung injury, J. Surg. Res., 42, 284-289 (1987).
44) Butler R.R. Jr. and Spicer K.M., Indomethacin and dexamethasone decrease oleic acid-induced pulmonary protein leak in rabbits, Circ. Shock, 20, 217-229 (1986).
45) Leeman M., de Beyl V.Z., Biarent D., Maggiorini M., Melot C. and Naeije R., Inhibition of cyclooxygenase and nitric oxide synthase in hypoxic vasoconstriction and oleic acid-induced lung injury, Am. J. Respir. Crit. Care Med., 159, 1383-1390 (1999).
46) Allison R.C., Marble K.T., Hernandez E.M., Townsley M.I. and Taylor A.E., Attenuation of permeability lung injury after phorbol myristate acetate by verapamil and OKY-046, Am. Rev. Respir.
Dis., 134, 93-100 (1986).
47) Sprague R.S., Stephenson A.H. and Lonigro A.J., OKY-046 prevents increases in LTB4 and pulmonary edema in phorbol ester-induced lung injury in dogs, J. Appl. Physiol., 73, 2493-2498 (1992).
48) Miyazawa T., Hiramoto M. and Hiramoto T., Reversal of oleic acid-induced respiratory distress by prostacyclin (PGI2), Respir. Physiol., 47: 351-364 (1982).
49) Nakazawa K., Yokoyama K., Matsuzawa Y., Makita K. and Amaha K., Pulmonary administration of prostacyclin (PGI2) during partial liquid ventilation in an oleic acid-induced lung injury: inhalation of aerosol or intratracheal instillation?, Intensive Care Med., 27, 243-245 (2001).
50) Lu M.Y., Kang B.H., Wan F.J., Chen C.S. and Huang K.L., Hyperbaric oxygen attenuates lipopolysaccharide-induced acute lung injury, Intensive Care. Med. 28, 636-641 (2002).
51) Goff C.D., Corbin R.S., Thies S.D., Frierson H.F.,Jr., Cephas G.A., Tribble C.G., Kron I.L. and Young J.F., Postinjury thromboxane receptor blockade ameliorates acute lung injury. Ann. Thorac. Surg., 64, 826-829 (1997).
52) Thies S.D., Corbin R.S., Goff C.D., Binns O.A.R., Buchanan S.A., Shockey K.S., Frierson H.F.,Jr, Young J.F., Tribble C.G. and Kron, I.L., Thromboxane receptor blockade improves oxygenation in an experimental model of acute lung injury, Ann. Thorac. Surg., 61, 1453-1457 (1996).
53) Moriuchi H., Kashiwada Y., Arai I., and Yuizono T., Effects of carbazochrome sodium sulfonate (AC-17) on oleic acid-induced lung injury, Pharmacol. Toxicolo., 77, 238-240 (1995).
54) Moriuchi H. and Yuizono T., Pentoxifylline prevents a decrease in arterial oxygen tension in oleic acid-induced lung injury, Crit. Care Med., 23, 357-364 (1995).
55) 森内 宏志, 由井薗 倫一, 低酸素血症治療薬の一次スクリーニング系-トラネキサム酸および塩酸プロカテ ロールの効果-, 日薬理誌, 103, 27-36 (1994).
56) Stephenson A.H., Lonigro A.J., Holmberg S.W. and Schuster D.P., Eicosanoid balance and perfusion redistribution of oleic acid-induced acute lung injury, J. Appl. Physiol., 73, 2126-2134 (1992).
57) 渡部 紀久子, 脂溶性シグナル分子の生合成と分解, 実験医学, 18, 144-152 (2000).
58) Altavilla D., Canale P., Squadrito F., Sardella A., Ammendolia L, Urna G., Ioculano M., Squadrito G.
and Caputi AP., Protective effects of BAY U 3405, a thromboxane A2 receptor antagonist, in endotoxin shock, Pharmacol. Res., 30, 137-151 (1994).
59) Ishizuka T., Sawada S., Sugama K. and Kurita A., Thromboxane A2 (TXA2) receptor blockade suppresses monocyte chemoattractant protein-1 (MCP-1) expression by stimulated vascular endothelial cells, Clin. Exp. Immunol., 120, 71-78 (2000).
60) Ishizuka T., Kawakami M., Hidaka T., Matsuki Y., Takamizawa M., Suzuki K., Kurita A. and Nakamura
H., Stimulation with thromboxane A2 (TXA2) receptor agonist enhances ICAM-1, VCAM-1 or ELAM-1 expression by human vascular endothelial cells, Clin. Exp. Immunol., 112, 464-70 (1998).
61) Lund T. and Osterud B., The promoting effect of epinephrine on lipopolysaccharide-induced interleukin-8 production in whole blood may be mediated by thromboxane A2, J. Thromb. Haemost., 1, 1042-1047 (2003).
62) Inoue Y., Tokuyama K., Nishimura H., Arakawa H., Kato M., Mochizuki H. and Morikawa A., Effects of STA2, a thromboxane A2 mimetic, in inducing airflow obstruction and airway microvascular leakage in guinea pigs, Pharmacology, 65, 62-68 (2002).
63) Squadrito F., Ioculano M., Altavilla D., Zingarelli B., Canale P., Campo G.M., Saitta A., Oriti S., Spignoli G. and Caputi A.P., G619, a dual thromboxane synthase inhibitor and thromboxane A2
receptor antagonist, reduces myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion in rats, Pharmacology, 47, 167-175 (1993).
64) Keelan J.A., Sato T.A., Gupta D.K., Marvin K.W. and Mitchell M.D., Prostanoid stimulation of cytokine production in an amnion-derived cell line: evidence of a feed-forward mechanism with implications for term and preterm labor, J. Soc. Gynecol. Investig., 7, 37-44 (2000).
65) Shimabukuro D.W., Sawa T. and Gropper M.A., Injury and repair in lung and airways, Crit. Care Med., 31(Suppl), S524-S531 (2003).
66) Abraham E., Neutrophils and acute lung injury, Crit. Care Med., 31(Suppl), S195-S199 (2003).
67) Fan J., Ye R.D., and Malik A.B., Transcriptional mechanisms of acute lung injury, Am. J. Physiol.
Lung Cell Mol. Physiol., 281, L1037-1050 (2001).
68) Kurdowska A, Noble J.M., Grant I.S., Robertson C.R., Haslett C. and Donnelly S.C., Anti-interleukin-8 autoantibodies in patients at risk for acute respiratory distress syndrome, Crit.
Care Med., 30, 2335-2337 (2002).
69) Kobayashi A., Hashimoto S., Kooguchi K., Kitamura Y., Onodera H., Urata Y. and Ashihara T., Expression of inducible nitric oxide synthase and inflammatory cytokines in alveolar macrophages of ARDS following sepsis, Chest, 113, 1632-1639 (1998).
70) Miller E.J., Cohen A.B., Nagao S., Griffith D, Maunder R.J., Martin T.R., Weiner-Kronish J.P., Sticherling M., Christophers E. and Matthay M.A., Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality, Am. Rev. Respir. Dis., 146, 427-132 (1992).
71) Goodman R.B., Strieter R.M., Martin D.P., Steinberg K.P., Milberg J.A., Maunder R.J., Kunkel S.L.,
Walz A., Hudson L.D. and Martin T.R., Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome, Am. J. Respir. Crit. Care Med., 154, 602-611 (1996).
72) Madjdpour L., Kneller S., Booy C., Pasch T., Schimmer R.C. and Beck-Schimmer B., Acid-induced lung injury: role of nuclear factor-kappaB, Anesthesiology, 99, 1323-1332 (2003).
73) Luster A.D., Chemokines--chemotactic cytokines that mediate inflammation, N. Engl. J. Med., 338, 436-445 (1998).
74) Saito N., Yamada Y., Sannohe S, Honda K., Adachi T., Kayaba H. and Chihara J., Possible involvement of C-C chemokines in functional augmentation of adhesion molecules in asthmatic patients, Lung, 180, 251-263 (2002).
75) Romagnani S., Cytokines and chemoattractants in allergic inflammation, Mol. Immunol., 38, 881-885 (2002).
76) Johnston C.J., Finkelstein J.N., Gelein R. and Oberdorster G., Pulmonary cytokine and chemokine mRNA levels after inhalation of lipopolysaccharide in C57BL/6 mice, Toxicol. Sci., 46, 300-307 (1998).
77) VanOtteren G.M., Strieter R.M., Kunkel S.L., Paine R.3rd., Greenberger M.J., Danforth J.M., Burdick M.D. And Standiford T.J., Compartmentalized expression of RANTES in a murine model of endotoxemia, J. Immunol., 154, 1900-1908 (1995).
78) Johnston C.J.,Finkelstein J.N., Oberdorster G., Reynolds S.D. and Stripp B.R., Clara cell secretory protein-deficient mice differ from wild-type mice in inflammatory chemokine expression to oxygen and ozone, but not to endotoxin, Exp. Lung Res., 25, 7-21 (1999).
79) Mori H., Tanaka H., Kawada K., Nagai H. and Koda A., Suppressive effects of tranilast on pulmonary fibrosis and activation of alveolar macrophages in mice treated with bleomycin: role of alveolar macrophages in the fibrosis, Jpn. J. Pharmacol., 67, 279-289 (1995).
80) Slotman G.J., Burchard K.W., D'Arezzo A. and Gann D.S., Ketoconazole prevents acute respiratory failure in critically ill surgical patients, J. Trauma, 28, 648-654 (1988).
81) Yu M. and Tomasa G., A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome, Crit. Care Med., 21, 1635-1642 (1993).
82) Sinuff T., Cook D.J., Peterson J.C. and Fuller H.D., Development, implementation, and evaluation of a ketoconazole practice guideline for ARDS prophylaxis, J. Crit. Care, 14, 1-6 (1999).